Last reviewed · How we verify

Azienda Ospedaliero, Universitaria Pisana — Portfolio Competitive Intelligence Brief

Azienda Ospedaliero, Universitaria Pisana pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Baricitinib Oral Tablet Baricitinib Oral Tablet phase 3 JAK inhibitor JAK1, JAK2 Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. AbbVie Inc. · 1 shared drug class
  3. Aclaris Therapeutics, Inc. · 1 shared drug class
  4. Arcutis Biotherapeutics, Inc. · 1 shared drug class
  5. Beijing Friendship Hospital · 1 shared drug class
  6. CAGE Bio Inc. · 1 shared drug class
  7. CTI BioPharma · 1 shared drug class
  8. Celgene · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Ospedaliero, Universitaria Pisana:

Cite this brief

Drug Landscape (2026). Azienda Ospedaliero, Universitaria Pisana — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliero-universitaria-pisana. Accessed 2026-05-17.

Related